drugset

drugset / Trial / NCT02042612

Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in Obese ICU Patients

NCT02042612 ↗

Phase 2 Completed 8 enrolled University Hospital, Clermont-Ferrand

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Describing a pharmacokinetic model of 48-h sevoflurane sedation in obese ICU patients

Timeline

Start: 2013-10
Primary completion: 2014-01
Completion: 2015-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sevoflurane	Other / unclassified	—	Inhaled

Indications